low accrual

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy used high-energy x-rays to damage tumor cells. It is not yet know whether chemotherapy followed by radiation therapy is more effective than chemotherapy given with radiation therapy for non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of chemotherapy and radiation therapy in treating patients who have unresectable stage I, stage II, or stage III non-small cell lung cancer.

OBJECTIVES:

• Compare survival, disease-free survival, local control, and pattern of recurrence in patients with unresectable stage I, II, or low-volume stage III non-small lung cancer treated with high-dose radiotherapy either preceded by induction chemotherapy with gemcitabine and cisplatin or combined with daily cisplatin.
• Compare the acute and late toxic effects of these regimens in these patients.
• Determine the quality of life of these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to performance status (0 vs 1), TNM stage, and participating center. Patients are randomized to one of two treatment arms.

• Arm I: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 3-6 hours on day 2. Treatment is repeated once 21 days later. Patients undergo high-dose accelerated conformal radiotherapy beginning on week 9 (day 57), 5 days a week, for 24 fractions, using a concurrent boost technique up to 66 Gy.
• Arm II: Patients receive low-dose cisplatin IV followed 1-2 hours later by high-dose accelerated conformal radiotherapy. Treatment continues daily, 5 days a week, for 24 fractions, using a concurrent boost technique up to 66 Gy.

Quality of life is assessed before treatment and at weeks 9-11, 19, 27, and 35.

Patients are followed at 3 weeks, 6-7 weeks, and then every 8 weeks thereafter.

PROJECTED ACCRUAL: A total of 418 patients (209 per arm) will be accrued for this study within 5 years.

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed non-small cell lung cancer

  • Stage I, II, III (T1-4, N0-3, M0)

    • No metastases to supraclavicular, contralateral hilar, or contralateral scalene lymph nodes

  • Medically inoperable or unresectable

• No pleural or pericardial effusion (except with repeated negative cytology)

PATIENT CHARACTERISTICS:

Age:

• Over 18

Performance status:

• ECOG 0 or 1

Life expectancy:

• Not specified

Hematopoietic:

• WBC at least 4,000/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin at least 6.8 g/dL
• No hemoptysis causing a decrease of hemoglobin of 1 g/dL or more within 24 hours

Hepatic:

• Not specified

Renal:

• Creatinine no greater than 1.25 times normal OR
• Creatinine clearance greater than 70 mL/min

Cardiovascular:

• No evidence of heart failure
• No myocardial infarction within the past 6 months
• No superior vena cava syndrome

Pulmonary:

• FEV1 at least 1 L
• No pre-existing fibrotic lung disease
• No postobstructive pneumonia preventing exact delineation of tumor volume
• Diffusion capacity at least 60%

Other:

• No weight loss of more than 10% in the past 3 months
• No uncontrolled infection
• No serious medical risk factors involving any of the major organ systems that would preclude adherence to the study treatment schedule

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No concurrent immunotherapy

Chemotherapy:

• No prior chemotherapy
• No other concurrent chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• No prior radiotherapy to the chest
• Maximum length of the esophagus receiving 40 Gy no greater than 18 cm
• Maximum length of the esophagus receiving 66 Gy no greater than 12 cm
• Must limit the spinal cord dose to a maximum of 50 Gy
• Must be able to exclude 25% of the heart from the boost volume

Surgery:

• Not specified

Other:

• No other concurrent experimental medications